Medivation Elects Kathryn Falberg to Board of Directors

Medivation Elects Kathryn Falberg to Board of Directors 
SAN FRANCISCO, CA -- (Marketwire) -- 02/04/13 --  Medivation, Inc.
(NASDAQ: MDVN) today announced that Kathryn E. Falberg has been
elected to the Company's Board of Directors. Ms. Falberg will also
serve as chair of the Audit Committee. 
"We are delighted to welcome an experienced pharmaceutical executive
of Kate's caliber to Medivation's board," said David Hung, M.D.,
president and chief executive officer of Medivation, Inc. "As prior
chief financial officer at Amgen and current chief financial officer
at Jazz Pharmaceuticals, Kate brings to our board critical and highly
relevant experience successfully leading pharmaceutical companies
through periods of rapid growth. Her financial acumen and strategic
business and commercial insight will be invaluable additions to our
board at a critical time of growth and transformation for
"I am honored to join the Medivation Board of Directors at such an
exciting time in the company's development," said Ms. Falberg. "I
admire Medivation's success in identifying and developing novel
therapies that treat diseases with limited therapeutic options and
look forward to providing strategic guidance to help further grow its
Ms. Falberg currently serves as the executive vice president and
chief financial officer of Jazz Pharmaceuticals plc. She also served
as its senior vice president and chief financial officer from 2009 to
2012. From 1995 through 2001, Ms. Falberg was with Amgen, Inc., where
she served as senior vice president Finance, Strategy and chief
financial officer, and before that as vice president, controller and
chief accounting officer, and vice president, treasurer. From 2001
through 2009, Ms. Falberg worked with a number of smaller companies
while also serving as a corporate director and audit committee chair
for several companies. Ms. Falberg received an M.B.A. and B.A. in
Economics from the University of California, Los Angeles and is a
Certified Public Accountant. Ms. Falberg currently serves on the
board, and is chair of the Audit Committee, of biopharmaceutical
company Halozyme Therapeutics, Inc.  
About Medivation  
Medivation, Inc. is a biopharmaceutical company focused on the rapid
development of novel therapies to treat serious diseases for which
there are limited treatment options. Medivation aims to transform the
treatment of these diseases and offer hope to critically ill patients
and their families. For more information, please visit us at 
Patrick Machado
Chief Business & Financial Officer
(415) 829-4101 
Anne Bowdidge
Sr. Director, Investor Relations
(650) 218-6900 
Press spacebar to pause and continue. Press esc to stop.